Publications
| 09/2019 | Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium. Isabelle Ray-Coquard, Ioana Braicu, Regina Berger, Sven Mahner, Jalid Sehouli, Eric Pujade-Lauraine, Philippe Alexandre Cassier, Ute Martha Moll, Hanno Ulmer, Karin Leunen, Alain Gustave Zeimet, Christian Marth, Ignace Vergote and Nicole Concin on behalf of the entire GANNET53 Consortium (18 Partner Institutions in Europe). Front Oncol. September 2019, Volume 9, Article 832; doi: 10.3389/fonc.2019.00832; Publication |
| 11/2018 | Polymer-Ligand-Based ELISA for Robust, High-Throughput, Quantitative Detection of p53 Aggregates. Maritschnegg E, Heinzl N, Wilson S, Deycmar S, Niebuhr M, Klameth L, Holzer B, Koziel K, Concin N, Zeillinger R. Anal Chem. 2018 Nov 20;90(22):13273-13279. doi: 10.1021/acs.analchem.8b02373.Publication |
| 11/2016 | Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitoticDNA fragmentation in ovarian cancer cells. Cell Death and Differentiation (2016), 1–17, Kramer D, Stark N, Schulz-Heddergott R, Erytch N, Edmunds S, Roßmann L, Bastians H, Concin N, Moll UM, Dobbelstein M. doi: 10.1038/cdd.2016.124. Publication |
Presentations to a Scientific Audience
| 09/2019 | 21st European Society of Gynaecological Oncology (ESGO) Congress, Athens, Greece; Abstract and presentation by Dr Adriaan Vanderstichele, KU Leuven: “TP53 mutations in cell-free DNA as early markers of therapeutic response in platinum-resistant relapsed ovarian cancer (PROC) — a prospective translational analysis of the phase II GANNET53 clinical trial”. Winner: Best Oral Communications / Late-Breaking Abstracts - Ovarian Cancer Presentation |
| 09/2019 | 21st European Society of Gynaecological Oncology (ESGO) Congress, Athens, Greece; Presentation by Prof. Nicole Concin, Innsbruck Medical University: “DNA repair interfering therapies beyond PARPi”. |
| 06/2019 | 2019 ASCO Annual Meeting, Chicago, USA; Abstract and poster: “EUDARIO/ENGOTov-48: A European multicenter randomized Phase II trial on the combination of the HSP90 inhibitor Ganetespib with Carboplatin followed by maintenance treatment with Niraparib (+/- Ganetespib) compared to platinum-based combination-chemotherapy followed by Niraparib in relapsed platinum-sensitive ovarian cancer patients”  |
| 09/2018 | 12th Biennial Ovarian Cancer Research Symposium, Seattle/Washington/USA; Abstract presented by Nicole Heinzl (Medical University of Vienna): “Identification of p53 Prions as an Independent Prognostic Marker for Survival in High-Grade Serous Ovarian Cancer” Link |
| 06/2018 | 2018 ASCO Annual Meeting, Chicago, USA, Abstract and poster: “Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high–‐grade serous, high–‐grade endometrioid, or undifferentiated, platinum–‐resistant epithelial ovarian, fallopian tube or primary peritoneal cancer”  |
| 11/2017 | 20th European Society of Gynaecological Oncology (ESGO) Congress, Vienna, Austria; Poster presented: “IDetection and Characterization of P53 Prions in High-Grade Serous Ovarian Cancer”  |
| 11/2017 | 20th European Society of Gynaecological Oncology (ESGO) Congress, Vienna, Austria; Poster presented: “P53 PROTEINS ARE ABLE TO EXHIBIT PRION-LIKE BEHAVIOUR - A STUDY TO ESTABLISH RELIABLE DETECTION TECHNIQUES IN OVARIAN TUMOURS”  |
| 09/2017 | 21. Onkologischer Alpengipfel Loas, Austria; Presentation held by Dr. Katarzyna Koziel: “p53 PROTEIN IS ABLE TO EXHIBIT PRION-LIKE BEHAVIOUR” |
| 11/2016 | AMP 2016 Annual Meeting, Charlotte, NC / USA; Abstract and Poster: “The use of a hybridisation-based NGS enrichment panel for the confident identification of a broad range of low frequency variants from as little as 50ng of challenging clinical research FFPE samples.”  |
| 05/2016 | Seventh Gynaecological Cancer Academy in Copenhagen/Denmark; Lecture held by Prof Nicole Concin: Title: “Molecular basis of ovarian cancer and therapeutic implications: p53” |
| 01/2016 | 19. Onkologischer Alpengipfel; 10.-12.9.2015; 40 Jahre translationale Forschung an der Frauenklinik Innsbruck, 40 Jahre Labor für Klinische Biochemie; Wissenschaftliche Rück- und Ausblicke; Presentation of the GANNET53 Clinical Trial |
| 10/2015 | 1st Ovarian Cancer Academy, 4th - 7th October 2015, Cluj-Napoca, Romania; Presentation held by Nicole Concin: “p53: targeting ovarian cancer at its roots” |
| 10/2015 | 9th International Meeting of the European Society of Gynaecological Oncology (ESGO 2015) in Nice, France, October 24-27, 2015; Presentation held by Nicole Concin in the session “New Targeted Treatments in Gynaecological Cancers”; Title: “Targeting HSP-90 in gynaecological cancer” |
| 05/2015 | 2015 ASCO Meeting, Chicago, Illinois; Abstract and poster presented by Prof. Isabelle Ray-Coquard (P7): “Part I of GANNET53: A multicentre phase I/II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer”.  |
| 04/2015 | 8th International Charité-Mayo-Conference: Updates in Gynecology: A Global Perspective; Berlin/Germany, Lecture held by Prof.Nicole Concin: “p53: targeting ovarian cancer at its roots” |
| 04/2015 | OR - Institute of Oncology Research, Bellinzona, Switzerland, Lecture held by Prof Nicole Concin: “Targeting p53: attacking ovarian cancer at the roots” |
| 03/2015 | 9e Rencontres Scientifiques du GINECO in Paris/France; lecture held by Nicole Concin (P1); Title: “Targeting p53: attacking ovarian cancer cell at the roots” |
| 09/2014 | Fourth Gynaecological cancer academy (GCA) Workshop in Frankfurt/Germany, Lecture held by Nicole Concin: “Inhibiting the gain-of-function of mutated p53” |
| 06/2014 | 16th International p53 Workshop, Stockholm, Sweden. Lecture held by Ute M. Moll (P11/UMG-GOE): “Exploiting tumor cell addiction to mutant p53 by pharmacological inhibition of the HSP90 chaperone axis in knocking mouse moddels”; Link: www.p53sweden2014.com |
| 10/2013 | 17th Oncologic Summit Loas, Tyrol, Austria. Lecture: “The tumor-promoting aspect of mutated p53 - therapeutic implications” Program |
| 10/2013 | 18th International Meeting of the European Society of Gynaecological Oncology (ESGO), Liverpool, UK. Poster presented on the GANNET53 Phase I trial  |
Press
| 06/2018 | Interview given by Prof. Concin regarding the EUDARIO trial to be conducted in the framework of the GANNET53 project for the online magazine Krebs:hilfe! during the ASCO Annual Meeting 2018, Chicago, USA Link: https://medonline.at/innere-medizin/onkologie/digital/asco-2018/2018/10006113/gannet53-studie-prueft-hsp-9-inhibitor-beim-ovarialkarzinom/; |
| 07/2016 | Press release by Angle PLC / UK on its cooperation with the GANNET53 consortium regarding sample analysing. 28.07.2016 Press release ; |
| 01/2016 | Article in MED INN Magazin der Medizinischen Universität Innsbruck: “Das mutierte Wächter-Gen [The mutated guardian of the genome].” (in German) Article; |
| 10/2015 | Article in FORUM MEDIZIN. Die Zeitung für medizinische Forschung, Lehre und Krankenversorgung. Supplement to Tiroler Tageszeitung [Tyrolean daily newspaper]: “Eierstockkrebs: Innovative Therapie. Erste Ergebnisse bei EU-Projekt GANNET53. [Ovarian cancer: innovative therapy. First results from EU project GANNET53].” (in German) Article |
| 08/2015 | Press release by Medical University of Innsbruck “Innovative Behandlung von Eierstockkrebs: Erste Ergebnisse bei EU-Projekt GANNET53” [Innovative Treatment of Ovarian Cancer: First Results in the GANNET53 EU project] 17.08.2015} |
| 08/2015 | Article in Der STANDARD [Austrian daily newspaper]: “Eierstockkrebs: Therapie für Frauen, die sonst chancenlos sind“ [Ovarian cancer: a therapy for woman with rare changes]; (in German) Link |
| 06/2015 | Press release by Synta Pharmaceuticals: “First Patient Enrolled in Phase 2 Portion of GANNET53 Study of Ganetespib in Ovarian Cancer” Press release |
| 04/2015 | Article published in Jatros HÄMATOLOGIE & ONKOLOGIE 4/15, p.230ff: “Innovative Therapie des Ovarialkarzinoms. p53-basierte Therapieansätze finden Einzug in die Klinik.“ Article |
| 04/2015 | Article in Gyn-Aktiv [Austrian gynaecological journal], issue 02/2015: “Status aktueller AGO Studien: GANNET53 [Status of ongoing AGO trials]“ |
| 12/2014 | Article in TIROLER BAUERNZEITUNG [Tyrolean farmers’ journal], issue 50: “Frauen und Krebs – ein höchst aktuelles Thema“ [women and cancer – a most topical subject] (in German) Article |
| 12/2014 | Article in DER MEDICUS, Journal der Hochschülerschaft an der Medizinischen Universität Innsbruck [journal of the students association at Innsbruck Medical University]; interview with Nicole Concin; issue 03/2014 (in German) Article |
| 11/2014 | Forum Land [lecture series organised by the Tyrolean Farmers’ Association]; lecture held by Nicole Concin in Pettna, Tyrol, Austria: “Neue Therapien bei Eierstockkrebs”[new therapies for ovarian cancer] |
| 07/2014 | Article in DIE PRESSE [Austrian daily newspaper]: “Krebsgen unter der Lupe” [cancer gene under the microscope] (in German) Article |
| 05/2014 | Article in GYN-AKTIV [Austrian gynaecological journal], issue 02/2014: “Auswahl aktueller AGO Studien” [Selected AGO trials] (in German) Article |
| 05/2014 | Article in TIROLER TAGESZEITUNG [Austrian daily newspaper]: „Mit neuem Medikament den stillen Krebs aufhalten” [Stop the silent cancer with new drug] |
| 05/2014 | Article in ECHO – Tirols erstes Nachrichtenmagazin [Tyrolean monthly magazine], issue 05/2014 (in German): “Innovative Wege” [innovative approaches] Article |
| 04/2014 | Special supplement in DER STANDARD [Austrian daily newspaper]: “FFG Forschungsefolge” [Austrian Research Promotion Agency: achievements in research] (in German) |
| 04/2014 | Article in Annual Report 2013 of the Austrian Research Promotion Agency FFG; presentation of the GANNET53 project |
| 01/2014 | Press release by SYNTA PHARMACEUTICALS Press release |
| 12/2013 | Article in the online magazine JOURNAL ONKOLOGIE”[oncologic journal]; Link |
| 12/2013 | Article in DER STANDARD [Austrian daily newspaper] (in German): “Rasterfandung in Krebszellen” [Dragnet investigation in cancer cells] (in German) Article |
| 11/2013 | Press information by STANDORTAGENTUR TIROL [Public agency of the Province of Tyrol/Austria for economic and scientific affairs] (in German) Press information |
| 11/2013 | Tiroler Standort Lunch in Vienna, Austria [event organized by the province of Tyrol to foster Tyrol as as econcomic and scientific location]; Nicole Concin presents the GANNET53 project: “GANNET53 - Eierstockkrebs innovativ therapieren“ [GANNET53 – innovative therapy for ovarian cancer] Program |
| 11/2013 | Press release by the GANNET53 CONSORTIUM (in German) Press release |
Project Meetings
| 02/2019 | 7th GANNET53 Consortium Meeting, Rome, Italy  |
| 01/2018 | 6th GANNET53 Consortium Meeting, Berlin, Germany  |
| 01/2017 | 5th GANNET53 Consortium Meeting, Innsbruck, Austria  |
| 01/2016 | 4th GANNET53 Consortium Meeting, Frankfurt, Germany  |
| 01/2015 | 3rd GANNET53 Consortium Meeting, Leuven, Belgium.  |
| 04/2014 | 2nd GANNET53 Consortium Meeting - Kick-off of Phase I Trial, Lyon, France.  |
| 10/2013 | GANNET53 Kick-off Meeting, Frankfurt, Germany. Agenda |
This project has received funding from the European Union’s Seventh Framework Programme for research,
technological development and demonstration under grant agreement no 602602.
© 2013 all rights reserved
/ LEGAL INFORMATION/ CONTACT